Correspondence 0001493152-23-024050 from ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc.
Date: July 7, 2023 · CIK: 0001859007 · Accession: 0001493152-23-024050
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272657
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences File No. 333-272657 (the “Registration Statement”) Acceleration Request Requested Date: July 10, Requested Time: 5:00 p.m., Eastern Time
Dear Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”) hereby requests that the above-referenced Registration Statement be declared effective by the Securities and Exchange Commission (the “Commission”) at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.
Please call Jack Hogoboom of Lowenstein Sandler LLP at (973) 587-2382 to confirm the effectiveness of the Registration Statement or with any questions.
Sincerely,
ZYVERSA THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
July
7, 2023
VIA
EDGAR
United
States Securities and Exchange Commission
Division
of Corporation Finance
Office
of Life Sciences
Mail
Stop 4720
100
F Street, N.E.
Washington,
D.C. 20549
Attn:
Joshua Gorsky
Re:
ZyVersa Therapeutics, Inc.
Registration Statement on Form S-1, as amended
File No. 333-272657 (the “Registration Statement”)
Acceleration Request
Requested
Date:
July 10,
2023
Requested Time:
5:00
p.m., Eastern Time
Dear
Ladies and Gentlemen:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended, ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”)
hereby requests that the above-referenced Registration Statement be declared effective by the Securities and Exchange Commission (the
“Commission”) at the “Requested Date” and “Requested Time” set forth above or at such later time
as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.
Please
call Jack Hogoboom of Lowenstein Sandler LLP at (973) 587-2382 to confirm the effectiveness of the Registration Statement or with any
questions.
Sincerely,
ZYVERSA THERAPEUTICS, INC.
By:
/s/
Stephen C. Glover
Name:
Stephen C. Glover
Title:
Chief Executive Officer